Abstract
Portal hypertension is a hemodynamic abnormality that involves a high risk of disability as well as a reduced life expectancy in patients with cirrhosis. Progress in the knowledge of pathophysiology of portal hypertension has opened a new perspective for different pharmacological approaches. In this context, the pleiotropic actions of statins on endothelial cell function have emerged as new options to reduce portal pressure levels by targeting multiple molecular pathways involved in hepatic vascular homeostasis. We highlight how statins may target some molecular pathways involved in the pathophysiology of portal hypertension and how these drugs may correct impaired hepatic vascular tone.
Keywords: Liver cirrhosis, statins, portal hypertension, hepatic stellate cell, intrahepatic vascular resistance, vascular endothelium
Current Vascular Pharmacology
Title:Statins and Portal Hypertension: A New Pharmacological Challenge
Volume: 10 Issue: 6
Author(s): Gonzalo Ramirez, Jimmy Briceno and Armando Rojas
Affiliation:
Keywords: Liver cirrhosis, statins, portal hypertension, hepatic stellate cell, intrahepatic vascular resistance, vascular endothelium
Abstract: Portal hypertension is a hemodynamic abnormality that involves a high risk of disability as well as a reduced life expectancy in patients with cirrhosis. Progress in the knowledge of pathophysiology of portal hypertension has opened a new perspective for different pharmacological approaches. In this context, the pleiotropic actions of statins on endothelial cell function have emerged as new options to reduce portal pressure levels by targeting multiple molecular pathways involved in hepatic vascular homeostasis. We highlight how statins may target some molecular pathways involved in the pathophysiology of portal hypertension and how these drugs may correct impaired hepatic vascular tone.
Export Options
About this article
Cite this article as:
Ramirez Gonzalo, Briceno Jimmy and Rojas Armando, Statins and Portal Hypertension: A New Pharmacological Challenge, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520918
DOI https://dx.doi.org/10.2174/157016112803520918 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors
Medicinal Chemistry Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design New Advances in Atrial Fibrillation Management: The Role of Apixaban
Current Drug Targets Basal Septal Hypertrophy
Current Cardiology Reviews Fructose Consumption, Lipid Metabolism and the Metabolic Syndrome
Current Nutrition & Food Science The Role of Statins in Oxidative Stress and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Catecholaminergic Strategies for the Treatment of Major Depression
Current Drug Targets Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design